The estimated Net Worth of Tatsuo Izumi is at least $1.33 million dollars as of 12 December 2013. Tatsuo Izumi owns over 71,270 units of Medicinova Inc stock worth over $1,176,000 and over the last 13 years Tatsuo sold MNOV stock worth over $149,667.
Sign up
Tatsuo Izumi MNOV stock SEC Form 4 insiders trading
Tatsuo has made over 6 trades of the Medicinova Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Tatsuo sold 71,270 units of MNOV stock worth $149,667 on 12 December 2013.
The largest trade Tatsuo's ever made was buying 158,730 units of Medicinova Inc stock on 13 May 2013 worth over $500,000. On average, Tatsuo trades about 41,153 units every 88 days since 2011. As of 12 December 2013 Tatsuo still owns at least 600,000 units of Medicinova Inc stock.
You can see the complete history of Tatsuo Izumi stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Tatsuo Izumi's mailing address?
Tatsuo's mailing address filed with the SEC is C/O MEDICINOVA, INC., 4350 LA JOLLA VILLAGE DRIVE, STE. 950, SAN DIEGO, CA, 92122.
Insiders trading at Medicinova Inc
Over the last 18 years, insiders at Medicinova Inc have traded over $200,908 worth of Medicinova Inc stock and bought 459,744 units worth $1,581,779 . The most active insiders traders include Jeff Himawan, Masatsune Okajima et Yuichi Iwaki. On average, Medicinova Inc executives and independent directors trade stock every 95 days with the average trade being worth of $74,094. The most recent stock trade was executed by Hideki Nagao on 28 November 2022, trading 6,754 units of MNOV stock currently worth $15,197.
What does Medicinova Inc's logo look like?
Complete history of Tatsuo Izumi stock trades at Medicinova Inc
Medicinova Inc executives and stock owners
Medicinova Inc executives and other stock owners filed with the SEC include:
-
Yuichi Iwaki,
President, Chief Executive Officer, Director -
Kazuko Matsuda,
Chief Medical Officer, Director -
Geoffrey O'brien,
Vice President -
Dr. Yuichi Iwaki M.D., Ph.D.,
Co-Founder, Pres, CEO & Exec. Director -
Dr. Kazuko Matsuda M.D., M.P.H., MPH, Ph.D.,
Chief Medical Officer & Director -
Hideki Nagao,
Independent Director -
Carolyn Beaver,
Director -
Edward Stepanow,
Chief Financial Officer -
Jeffrey Himawan,
Independent Chairman of the Board -
John O'Neil CPA,
Controller -
Dr. David H. Crean Ph.D.,
Chief Bus. Officer -
Dr. Federico Gaeta Ph.D.,
Chief Scientific Officer -
Douglas G Paulin CPA, CPA,
Chief Financial Officer -
Yutaka Kobayashi,
Director -
Yoshio Ishizaka,
Director -
Masatsune Okajima,
VP and Head of Japanese Office -
Federico C.A. Gaeta,
Chief Scientific Officer -
Tatsuo Izumi,
Director -
Den Boom Esther Van,
Chief Financial Officer -
Jeff Himawan,
Director -
John K A Prendergast,
Director -
Hiroaki Shigeta,
Director -
Kirk William Johnson,
Chief Scientific Officer -
Arlene Morris,
Director -
Michael Denis Coffee,
Chief Business Officer -
David D O'toole,
Director -
Alan W Dunton,
Director -
Shintaro Asako,
VP and Chief Financial Officer -
Richard E Sr Gammans,
Chief Development Officer -
Daniel Vapnek,
Director -
Kenneth W Locke,
Chief Scientific Officer -
Michael E Kalafer,
Chief Medical Officer -
Nicole Lemerond,
Director